On September 11, HANSOH PHARMA fell 3.06% in regular trading, trading at HK$32.44/share, with turnover of approximately HK$79.90 million. The stock has now declined for multiple consecutive sessions after surging 16.01% on August 27 following the release of better-than-expected interim results.

The broader pharmaceutical sector remains under pressure, with peers CSPC Pharmaceutical down 1.94%, China Biologic Products down 3.28%, and Hengrui Medicine down 1.05%, reflecting broad-based weakness across the sector. Despite strong first-half fundamentals — revenue of RMB 8.304 billion (up 11.7% YoY), attributable profit of RMB 4.258 billion (up 35.8% YoY), and innovative drug revenue reaching a record 85.4% of total sales — the stock continues to face profit-taking pressure. Major investment banks including Goldman Sachs, J.P. Morgan, and CLSA have raised target prices to a range of HK$43.7 to HK$52.7, but elevated short-selling ratios prior to the earnings release and persistent sector headwinds have weighed on sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)